A randomised controlled trial of succinylated gelatin (4%) fluid on urinary acute kidney injury biomarkers in cardiac surgical patients.
Cardiac surgery
Colloid
Fluid resuscitation
Renal
Urine
Journal
Intensive care medicine experimental
ISSN: 2197-425X
Titre abrégé: Intensive Care Med Exp
Pays: Germany
ID NLM: 101645149
Informations de publication
Date de publication:
22 Sep 2021
22 Sep 2021
Historique:
received:
15
02
2021
accepted:
13
08
2021
entrez:
22
9
2021
pubmed:
23
9
2021
medline:
23
9
2021
Statut:
epublish
Résumé
Fluid resuscitation is frequently required for cardiac surgical patients admitted to the intensive care unit. The ideal fluid of choice in regard to efficacy and safety remains uncertain. Compared with crystalloid fluid, colloid fluid may result in less positive fluid balance. However, some synthetic colloids are associated with increased risk of acute kidney injury (AKI). This study compared the effects of succinylated gelatin (4%) (GEL) with compound sodium lactate (CSL) on urinary AKI biomarkers in patients after cardiac surgery. Cardiac surgical patients who required an intravenous fluid bolus of at least 500 mL postoperatively were randomly allocated to receive GEL or CSL as the resuscitation fluid of choice for the subsequent 24 h. Primary outcomes were serial urinary neutrophil gelatinase-associated lipocalin (NGAL) and cystatin C concentrations measured at baseline, 1 h, 5 h and 24 h after enrolment, with higher concentrations indicating greater kidney injury. Secondary biomarker outcomes included urinary clusterin, α1-microglobulin and F Forty cardiac surgical patients (n = 20 per group) with similar baseline characteristics were included. There was no significant difference in the median volume of fluid boluses administered over 24 h between the GEL (1250 mL, Q1-Q3 500-1750) and CSL group (1000 mL, Q1-Q3 500-1375) (P = 0.42). There was a significantly greater increase in urinary cystatin C (P < 0.001), clusterin (P < 0.001), α1-microglobulin (P < 0.001) and F This preliminary randomised controlled trial showed that use of succinylated gelatin (4%) for fluid resuscitation after cardiac surgery was associated with increased biomarker concentrations of renal tubular injury and dysfunction, compared to crystalloid fluid. These results generate concern that use of intravenous gelatin fluid may contribute to clinically relevant postoperative AKI. Trial registration ANZCTR.org.au, ACTRN12617001461381. Registered on 16th October, 2017, http://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373619&isReview=true .
Sections du résumé
BACKGROUND
BACKGROUND
Fluid resuscitation is frequently required for cardiac surgical patients admitted to the intensive care unit. The ideal fluid of choice in regard to efficacy and safety remains uncertain. Compared with crystalloid fluid, colloid fluid may result in less positive fluid balance. However, some synthetic colloids are associated with increased risk of acute kidney injury (AKI). This study compared the effects of succinylated gelatin (4%) (GEL) with compound sodium lactate (CSL) on urinary AKI biomarkers in patients after cardiac surgery.
METHODS
METHODS
Cardiac surgical patients who required an intravenous fluid bolus of at least 500 mL postoperatively were randomly allocated to receive GEL or CSL as the resuscitation fluid of choice for the subsequent 24 h. Primary outcomes were serial urinary neutrophil gelatinase-associated lipocalin (NGAL) and cystatin C concentrations measured at baseline, 1 h, 5 h and 24 h after enrolment, with higher concentrations indicating greater kidney injury. Secondary biomarker outcomes included urinary clusterin, α1-microglobulin and F
RESULTS
RESULTS
Forty cardiac surgical patients (n = 20 per group) with similar baseline characteristics were included. There was no significant difference in the median volume of fluid boluses administered over 24 h between the GEL (1250 mL, Q1-Q3 500-1750) and CSL group (1000 mL, Q1-Q3 500-1375) (P = 0.42). There was a significantly greater increase in urinary cystatin C (P < 0.001), clusterin (P < 0.001), α1-microglobulin (P < 0.001) and F
CONCLUSIONS
CONCLUSIONS
This preliminary randomised controlled trial showed that use of succinylated gelatin (4%) for fluid resuscitation after cardiac surgery was associated with increased biomarker concentrations of renal tubular injury and dysfunction, compared to crystalloid fluid. These results generate concern that use of intravenous gelatin fluid may contribute to clinically relevant postoperative AKI. Trial registration ANZCTR.org.au, ACTRN12617001461381. Registered on 16th October, 2017, http://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373619&isReview=true .
Identifiants
pubmed: 34549356
doi: 10.1186/s40635-021-00412-9
pii: 10.1186/s40635-021-00412-9
pmc: PMC8455786
doi:
Banques de données
ANZCTR
['ACTRN12617001461381']
Types de publication
Journal Article
Langues
eng
Pagination
48Subventions
Organisme : Royal Perth Hospital Medical Research Foundation
ID : MRF 2017-32
Informations de copyright
© 2021. The Author(s).
Références
Eur J Cardiothorac Surg. 2011 Jan;39(1):38-43
pubmed: 20650648
Crit Care. 2014 Jul 14;18(4):R151
pubmed: 25023056
BMJ. 2010 Mar 23;340:c869
pubmed: 20332511
Nephrol Dial Transplant. 2014 Jul;29(7):1301-11
pubmed: 24385545
Exp Toxicol Pathol. 2012 Nov;64(7-8):797-805
pubmed: 21377848
Eur J Cardiothorac Surg. 2012 Apr;41(4):734-44; discussion 744-5
pubmed: 22378855
J Crit Care. 2016 Oct;35:75-83
pubmed: 27481739
Clin Chim Acta. 2012 Oct 9;413(19-20):1446-53
pubmed: 22683781
J Vet Emerg Crit Care (San Antonio). 2019 Mar;29(2):132-142
pubmed: 30767375
Cardiovasc Res. 2006 Feb 15;69(3):562-73
pubmed: 16405877
Perfusion. 2010 Sep;25(5):283-91
pubmed: 20630920
Br J Anaesth. 2014 Feb;112(2):255-64
pubmed: 24169821
Anal Biochem. 2014 Mar 15;449:129-31
pubmed: 24380789
Acta Anaesthesiol Scand. 2020 Nov;64(10):1438-1445
pubmed: 32735701
Clin Chem. 2004 Mar;50(3):552-8
pubmed: 14709451
Anesthesiology. 2006 Sep;105(3):485-91
pubmed: 16931980
Anesth Analg. 2007 Oct;105(4):905-17, table of contents
pubmed: 17898365
Perioper Med (Lond). 2017 Oct 19;6:15
pubmed: 29075482
Am J Kidney Dis. 2014 Apr;63(4):567-72
pubmed: 24200462
Ann Intern Med. 2006 Aug 15;145(4):247-54
pubmed: 16908915
Clin J Am Soc Nephrol. 2010 Dec;5(12):2154-65
pubmed: 20798258
J Am Soc Nephrol. 2003 Oct;14(10):2534-43
pubmed: 14514731
Crit Care. 2012 Jan 25;16(1):R16
pubmed: 22277099
Biomarkers. 2009 Sep;14(6):423-31
pubmed: 19572801
Circulation. 2009 May 12;119(18):2444-53
pubmed: 19398670
Perfusion. 2018 Nov;33(8):630-637
pubmed: 29871564
J Cardiothorac Vasc Anesth. 2017 Oct;31(5):1624-1629
pubmed: 28778778
Biomarkers. 2013 Feb;18(1):95-101
pubmed: 23167703
Lancet. 2005 Apr 2-8;365(9466):1231-8
pubmed: 15811456
J Cardiothorac Vasc Anesth. 2020 Oct;34(10):2674-2681
pubmed: 32402699
Br J Anaesth. 1998 Aug;81(2):198-202
pubmed: 9813523
Kidney Int. 1991 Jun;39(6):1156-61
pubmed: 1910124
J Am Soc Nephrol. 2011 Sep;22(9):1748-57
pubmed: 21836143
N Engl J Med. 2012 Nov 15;367(20):1901-11
pubmed: 23075127
Intensive Care Med. 2010 Mar;36(3):541-8
pubmed: 19890625
J Thorac Cardiovasc Surg. 2012 Mar;143(3):682-688.e1
pubmed: 22054657
Acta Anaesthesiol Scand. 2005 Mar;49(3):373-8
pubmed: 15752404
Intensive Care Med. 2006 Jul;32(7):1030-8
pubmed: 16791665
Crit Care Med. 2013 Nov;41(11):2532-42
pubmed: 23978813
Vet Clin Pathol. 2019 Dec;48(4):710-715
pubmed: 31820457
J Clin Invest. 1994 May;93(5):2175-88
pubmed: 7910173
Nephrol Dial Transplant. 2019 Feb 1;34(2):308-317
pubmed: 30053231
Clin J Am Soc Nephrol. 2010 Dec;5(12):2229-35
pubmed: 20829422
J Biol Chem. 1993 May 15;268(14):10425-32
pubmed: 7683678
HSR Proc Intensive Care Cardiovasc Anesth. 2010;2(4):287-96
pubmed: 23439737
Am J Kidney Dis. 2008 Sep;52(3):425-33
pubmed: 18649981
J Clin Pathol. 1983 Mar;36(3):253-9
pubmed: 6186698
Biomarkers. 2011 Nov;16(7):553-66
pubmed: 21955166